The Mainstreaming Addiction Treatment Act and Pharmacist-Prescribed Buprenorphine
This study examines the impact of the MAT Act on trends in pharmacist-prescribed buprenorphine from US retail pharmacies from 2019 to 2024.
Authors
- Christina A. Mikosz (ORCID: https://orcid.org/0000-0002-5228-6480)
- Emmy L. Tran (ORCID: https://orcid.org/0000-0002-2643-0397)
- Gery P. Guy (ORCID: https://orcid.org/0000-0003-1553-661X)
- S. Michaela Rikard (ORCID: https://orcid.org/0000-0003-2666-8722)
Institutions
- Centers for Disease Control and Prevention (US)
- National Center for Injury Prevention and Control (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1001/jama.2025.7151
- Citations
- 2
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.76